

# Intraocular Pressure Decrease Does Not Affect Blood Flow Rate of Ophthalmic Artery in Ocular Hypertension

Gauti Jóhannesson,<sup>1,2</sup> Sara Qvarlander,<sup>3,4</sup> Anders Wåhlin,<sup>3-5</sup> Khalid Ambarki,<sup>3</sup> Per Hallberg,<sup>4,6</sup> Anders Eklund,<sup>3,4</sup> and Christina Lindén<sup>1</sup>

<sup>1</sup>Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden

<sup>2</sup>Wallenberg Center for Molecular Medicine, Umeå University, Umeå, Sweden

<sup>3</sup>Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå, Sweden

<sup>4</sup>Centre for Biomedical Engineering and Physics, Umeå University, Umeå, Sweden

<sup>5</sup>Umeå Center for Functional Brain Imaging, Umeå University, Umeå, Sweden

<sup>6</sup>Department of Applied Physics and Electronics, Umeå University, Umeå, Sweden

Correspondence: Gauti Jóhannesson, Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden; [gauti.johannesson@umu.se](mailto:gauti.johannesson@umu.se).

Received: June 26, 2020

Accepted: September 24, 2020

Published: October 19, 2020

Citation: Jóhannesson G, Qvarlander S, Wåhlin A, et al. Intraocular pressure decrease does not affect blood flow rate of ophthalmic artery in ocular hypertension. *Invest Ophthalmol Vis Sci.* 2020;61(12):17. <https://doi.org/10.1167/iovs.61.12.17>

**PURPOSE.** To investigate if decrease of IOP affects the volumetric blood flow rate in the ophthalmic artery (OA) in patients with previously untreated ocular hypertension.

**METHODS.** Subjects with untreated ocular hypertension ( $n = 30$ ; mean age  $67 \pm 8$  years; 14 females) underwent ophthalmologic examination and a 3-Tesla magnetic resonance imaging investigation. The magnetic resonance imaging included three-dimensional high-resolution phase-contrast magnetic resonance imaging to measure the OA blood flow rate. The subjects received latanoprost once daily in the eye with higher pressure, the untreated eye served as control. The same measurements were repeated approximately 1 week later.

**RESULTS.** The mean OA blood flow rate before and after treatment was  $12.4 \pm 4.4$  and  $12.4 \pm 4.6$  mL/min in the treated eye (mean  $\pm$  SD;  $P = 0.92$ ) and  $13.5 \pm 5.2$  and  $13.4 \pm 4.1$  mL/min in the control eye ( $P = 0.92$ ). There was no significant difference between the treated and control eye regarding blood flow rate before ( $P = 0.13$ ) or after treatment ( $P = 0.18$ ), or change in blood flow rate after treatment ( $0.1 \pm 3.1$  vs.  $-0.1 \pm 4.0$  mL/min,  $P = 0.84$ ). Latanoprost decreased the IOP by  $7.2 \pm 3.1$  mm Hg in the treated eye ( $P < 0.01$ ).

**CONCLUSIONS.** The results indicate that a significant lowering of IOP does not affect the blood flow rate of the OA in ocular hypertension subjects. The ability to maintain blood supply to the eye independent of the IOP could be a protective mechanism in preserving vision in subjects with ocular hypertension.

Keywords: magnetic resonance imaging, blood flow, ophthalmic artery, intraocular pressure

A common denominator for all types of glaucoma is the progressive optic neuropathy with corresponding visual field defects.<sup>1</sup> Although it is the leading cause of irreversible blindness worldwide,<sup>2</sup> the pathophysiology of glaucoma is still not fully understood. The most important risk factor for the development<sup>3</sup> and progression of glaucoma<sup>4</sup> is an elevated IOP. To date, this is also the only treatable risk factor and all current glaucoma treatment is focused on the lowering of IOP. However, despite considerable IOP decrease and low IOP, many patients still progress at an unacceptable rate, indicating that there are other important aspects of the pathophysiology of glaucoma than an elevated IOP.

Apart from the predominant theory of mechanical insult to the retinal ganglion cells owing to raised IOP, disturbed ocular blood flow has been proposed as a potential contributing factor of glaucoma pathophysiology.<sup>5</sup> Thus, there is an interest in blood flow in glaucomatous eyes, and it has been suggested that autoregulation is not fully capable

of compensating aberrant IOP levels.<sup>6,7</sup> This finding calls for investigating the relationship between these two suggested main components in glaucoma pathophysiology.

The arterial blood supply of the ocular system and optic nerve is primarily provided by main branches of the ophthalmic artery (OA), that is, the central retinal artery and the ciliary arteries.<sup>5</sup> Phase-contrast magnetic resonance imaging (PCMRI) is a noninvasive technique to quantify the blood flow rate during a cardiac cycle.<sup>8,9</sup> Traditionally, PCMRI has only been used to measure larger arteries (>2 mm diameter) intracranially. However, by prioritizing high resolution in the sequence setup, it is possible to accurately measure volumetric blood flow rate in small arteries such as the OA, which has a diameter of approximately 1.5 mm.<sup>10</sup>

As pointed out recently by Harris et al,<sup>11</sup> imaging of the retrobulbar blood supply has been restricted to color Doppler imaging (CDI) which main limitation is that CDI

is unable to quantify blood flow. By assessment of blood vessel diameter, the PCMRI technique meets this unmet need.

The interplay between IOP and blood flow to the eye is not entirely known. To address this knowledge gap, we used high-resolution PCMRI to test our hypothesis that a significant IOP reduction would result in increased blood flow in the OA. Because glaucomatous damage in itself, irrespective of IOP level, may cause disturbed blood flow, we chose to include subjects with elevated IOP but no glaucomatous damage in the study.

## METHODS

This prospective, single-center study analyzed subjects diagnosed with untreated ocular hypertension who were monitored at the Department of Ophthalmology at Umeå University Hospital in Umeå, Sweden. The study followed the tenets of the Declaration of Helsinki and was approved by the Regional Ethical Review Board at Umeå University. All participants signed a written informed consent after oral and written information of the study. The study was registered at clinicaltrials.gov (ID: NCT02656979).

Subjects with untreated ocular hypertension and normal visual fields were asked to participate. Forty-seven subjects were included; of these, 17 subjects were excluded from final analysis owing to latanoprost being instilled in both eyes ( $n = 1$ ), patient unable to perform MRI ( $n = 1$ ), withdrawal of informed consent before the second MRI scan ( $n = 4$ ), nonmeasurable OA blood flow likely owing to anatomic variations where OA originates from the middle meningeal artery ( $n = 2$ ), missing data ( $n = 3$ ), or poor quality MRI data ( $n = 6$ ) in either the treatment or control eye at any visit. Thus, 30 subjects with complete data were analyzed.

The study included two visits for each subject. After the first visit, the participants received a bottle of latanoprost. They were instructed to instill one drop in the eye with the highest pressure once daily until the second visit approximately 1 week later, when all measurements were repeated. At each visit, subjects were assessed with an ophthalmology examination as outlined elsewhere in this article, an MRI scan, and in conjunction with the MRI a blood pressure measurement in a sitting position. The ocular perfusion pressure (OPP) in supine position for each eye was calculated as 115/130 of the mean arterial pressure, minus the IOP; the mean arterial blood pressure was calculated as the diastolic blood pressure plus one-third of the difference between systolic and diastolic blood pressure.<sup>11,12</sup>

## Ophthalmology Examinations

Apart from a standard ocular examination, the participants underwent the following ophthalmologic investigations at both visits: measurement of axial length (AL) with IOLMaster (Carl Zeiss Meditec AG, Jena, Germany), central corneal thickness and corneal curvature with a Scheimpflug camera (Pentacam, Oculus GmbH, Wetzlar, Germany), corneal hysteresis (CH) with an Ocular Response Analyser (Reichert Ophthalmic Instruments, Inc., Buffalo, NY), and IOP with Goldmann Applanation Tonometry (Haag-Streit, Bern, Switzerland).

## MRI Protocol

On the same days as the ophthalmologic examinations, an MRI scan of the brain was performed with a 3T scanner (GE Discovery MR 750, General Electric Healthcare, Waukesha, WI) with a 32-channel head coil. The same measurements were performed at both visits and followed a detailed protocol previously described (Ambarki 2013).<sup>10</sup> For localization of the OA, a three-dimensional time-of-flight MR angiography sequence was used. Flow was then measured with a two-dimensional PCMRI sequence, with the imaging plane placed perpendicularly to the OA, approximately 10 mm distally of the bifurcation from the internal carotid artery. The location was chosen where the artery was relatively straight and not immediately adjacent to the air-filled sinuses. The PCMRI sequence parameters were: velocity encoding 35 cm/s, TR/TE 9/5 ms, flip angle 15°, acquisition matrix 512 × 512, field of view 180 × 180 mm<sup>2</sup>, six views per segment, and two signal averages. The resultant image resolution was 0.35 × 0.35 mm<sup>2</sup>. A peripheral pulse detector was used for retrospective cardiac gating and 32 timeframes were reconstructed, corresponding with a full cardiac cycle.

## PCMRI Analysis

To quantify the flow, the PCMRI data was analyzed using the software Segment (version 1.8, <http://medviso.com/segment/>).<sup>13</sup> A region of interest was manually drawn around the vessel in the magnitude image, with adjustments made based on the signal in the phase image. The region of interest was drawn so that the whole vessel was included during the entire cardiac cycle, with the size and position of the region of interest kept constant across all cardiac timeframes. Eddy current correction ("background correction") of the flow velocities was performed using the automated tool of the Segment software.

For each measurement, mean OA blood flow rate was calculated as the average flow rate over the cardiac cycle. The pulsatility index (PI) was calculated as the difference between the maximum and minimum flow rates over the cardiac cycle, divided by the mean flow rate.

## Statistical Analysis

Treated and control eyes were compared using paired samples *t* tests. Changes in flow and IOP after treatment were also assessed with paired sample *t* tests. Correlations between blood flow, PI, and ocular measurement were analyzed using Spearman's rho (rank correlation), because three of the relevant parameters were not normally distributed (according to a Kolmogorov–Smirnov and/or Shapiro–Wilk test). Analyses where the *P* value was less than 0.05 were considered as statistically significant. In the power analysis, the flow of OA is expected to be 10 mL/min,<sup>10</sup> and we assumed that a change of 20%, that is, 2 mL/min, would be clinically relevant. Furthermore, assuming a within-subject variability of 3 mL/min in standard deviation and 80% power, the sample size was estimated as 36 subjects.

## RESULTS

Patient demographics and ophthalmologic measurements are presented in Table 1. Blood flow rate and PI before and after treatment are presented in Table 2. Latanoprost

**TABLE 1.** Patient Demographics and Ophthalmologic Measurements

Age (range)	67 ± 8 years	
Sex (M/F)	16/14	
Blood pressure (systolic/diastolic)	159.1 ± 18.3/93.6 ± 12.9 mm Hg	
	Treated eye ( <i>n</i> = 30)	Control eye ( <i>n</i> = 30)
IOP at inclusion (mm Hg)	28.5 ± 4.4	23.7 ± 4.6
AL (mm)	23.6 ± 1.0	23.5 ± 1.0
Central corneal thickness (μm)	556 ± 36	558 ± 33
Corneal curvature (mm)	44.5 ± 1.3	44.4 ± 1.3
CH (mm Hg)	9.3 ± 2.6	10.4 ± 1.9

**TABLE 2.** OA Blood Flow (Q) and PI Before and After Treatment

	Treated Eye	Control Eye	<i>P</i> Value (Treatment vs. Control)
Blood flow rate before (mL/min)	12.4 ± 4.6	13.5 ± 5.2	0.13
Blood flow rate after (mL/min)	12.4 ± 4.4	13.4 ± 4.1	0.18
Change in blood flow rate (after - before) (mL/min)	0.1 ± 3.1	-0.1 ± 4.0	0.84
<i>P</i> value (before vs. after)	0.92	0.92	
PI before	1.2 ± 0.3	1.2 ± 0.3	0.23
PI after	1.2 ± 0.3	1.2 ± 0.3	0.37
Change in PI (after - before)	0.0 ± 0.3	0.0 ± 0.3	0.98
<i>P</i> value (before vs after)	0.84	0.80	

decreased the IOP by  $7.2 \pm 3.1$  mm Hg ( $P < 0.01$ ) in the treated eye, with no significant effect in the untreated control eye (mean change,  $-0.3 \pm 1.8$  mm Hg;  $P = 0.44$ ). There was no significant effect on the mean blood flow rate of the treated eye ( $P = 0.92$ ). Measured changes in the blood flow rate after treatment did not differ between the treated and control eye and there was no difference between the eyes at the first visit (Table 2).

The blood pressure after treatment (systolic,  $161.6 \pm 20.7$  mm Hg; diastolic,  $92.6 \pm 10.8$  mm Hg) was not significantly different from before treatment ( $P = 0.45$  and  $P = 0.65$ , respectively). The OPP in the treated eye was  $78.2 \pm 11.2$  mm Hg before treatment and increased significantly after treatment ( $85.6 \pm 11.0$ ;  $P < 0.01$ ). The OPP in the control eye was not significantly changed between the two visits (before,  $82.8 \pm 11.7$  mm Hg; after,  $83.2 \pm 11.7$  mm Hg;  $P = 0.84$ ). The OPP was significantly lower in the treated eye than the control eye before treatment ( $P < 0.01$ ), and significantly higher after treatment ( $P < 0.01$ ).

In a post hoc test analyzing only those subjects where the IOP of the treated eye was decreased by at least 5 mm Hg, no difference was seen between the treated and control eyes ( $n = 23$ ; change in blood flow rate,  $0.4 \pm 3.2$  mL/min (treated eyes) vs  $0.1 \pm 3.8$  mL/min (control eyes);  $P = 0.70$ )

Regarding biomechanical parameters, the AL of the treated eyes showed a small but significant reduction after treatment ( $23.59 \pm 0.98$  mm vs.  $23.53 \pm 0.98$  mm;  $P < 0.01$ ) and the CH increased significantly ( $9.3 \pm 2.7$  mm Hg vs.  $10.5 \pm 1.7$  mm Hg;  $P < 0.01$ ;  $n = 29$ ) (no corresponding effect in the control eye;  $P = 0.32$ ). There were no significant changes in central corneal thickness or corneal curvature of the treated eye ( $P \geq 0.1$ ).

There was a significant correlation between PI and IOP (Spearman's rho,  $-0.39$ ;  $P < 0.05$ ) before treatment, but this correlation was not significant after treatment ( $P > 0.8$ ). There was no rank correlation between blood flow rate and IOP in the treated eye ( $P = 0.13$ ). Neither blood flow rate

nor PI in the treated eye correlated significantly to OPP, AL, CH, central corneal thickness, or corneal curvature before treatment, although there was a trend between PI and AL (rho,  $-0.36$ ;  $P = 0.053$  for PI vs. AL; otherwise,  $P \geq 0.13$ ).

Although the eddy current correction affected the magnitude of the blood flow values, the results when analyzing changes in blood flow with treatment were similar for uncorrected values (i.e., no change with treatment).

## DISCUSSION

This study is the first to use PCMRI to investigate changes in volumetric blood flow rate after lowering of IOP. Assuming a physiologically relevant change of 2 mL/min in the power calculations, this study showed that the blood flow rate of the OA was not altered by a decrease in IOP in subjects with ocular hypertension. As expected, the OPP was significantly increased in the treated eye and, because the blood pressure remained unchanged between the visits, this increase in OPP can be explained by the localized reduction in IOP.

Measurements of blood flow velocity in the OA have previously been performed with a CDI technique where IOP has been lowered. Similarly to us, Marjanovic et al.<sup>14</sup> used latanoprost to reduce IOP and found no change in retrobulbar velocity parameters. This finding is further supported by Harris et al.<sup>15</sup> and Hommer et al.,<sup>16</sup> where a decrease in the IOP induced by prostaglandins did not alter retrobulbar flow velocities. However, contradictory results also exist where latanoprost as only therapy,<sup>17</sup> or together with timolol,<sup>18</sup> have been shown to increase velocity in OA.

There are several potential explanations for our findings. First, ocular blood flow autoregulation could contribute. Ocular autoregulation is the capability to uphold an appropriate level of blood flow to the eye during varying metabolic demand and in the presence of changes in OPP.<sup>19</sup> Under

healthy conditions, this balance is maintained, but a defective autoregulation has been proposed to play an important role in the pathophysiology of ocular diseases such as glaucoma.<sup>20</sup> Despite an elevated IOP, the pretreatment blood flow in this group was in the same range as data for healthy controls measured with the same PCMRI technique.<sup>10</sup> Given that ocular hypertensive subjects can be considered to be healthy, it is possible that the blood flow was unaffected prior to IOP lowering and, thus, an increase in blood flow would not occur when the IOP was decreased. This finding is supported by the lack of difference between the blood flow rate in the control and treated eyes before treatment, despite a significant difference in IOP. In other words, the autoregulation was likely functioning adequately and maintained a normal blood flow level in the studied subjects before treatment. It has been suggested that the upper limit for the autoregulation of retinal blood flow is approximately at IOP of 30 mm Hg<sup>6,7</sup>; this finding is supported by Tribble and Andersson,<sup>21</sup> who reported a decreased velocity measured with CDI in the central retinal artery after artificially increasing the IOP to 30 mm Hg. This is higher than the mean IOP of our ocular hypertensive subjects, but a subanalysis of subjects with an IOP of 30 mm Hg or greater ( $n = 7$ ) did not change these results. In patients with glaucoma with possible deficient autoregulation, it has been suggested that this upper limit of autoregulation could be lower causing hypoperfusion at an IOP of approximately 25 mm Hg.<sup>22</sup> Based on the present results, this type of deficiency does not seem to occur in ocular hypertension.

Second, is it possible that the lack of altered blood flow could be due to an insufficient IOP-lowering effect of latanoprost treatment in this study? To answer this question, we performed a subanalysis of subjects with an IOP reduction of at least 5 mm Hg and this analysis did not change the results.

Third, the retrobulbar arterial anatomy may elucidate the results. Although the OA is the main supplier of blood to the ocular system, a considerable amount of the blood is conveyed to extraocular tissues.<sup>23</sup> In fact, calculations based on previously published data on number of vessels and vessel area<sup>23</sup> as well as flow,<sup>24</sup> indicate that only approximately 15% to 20% of the blood flow in the OA is delivered onward to the central retinal artery and the ciliary arteries supplying the eye. Furthermore, the OA, originating from the internal carotid artery, anastomoses with vessels from the external carotid artery circulation. Albeit small, the OA could be too large and proximal a vessel to study a possible effect on blood flow owing to reduced IOP. Being end arteries and solely providing blood to the ocular system, the ciliary and retinal arteries would thus be preferable for studying a possible effect of IOP reduction on ocular blood flow. However, the resolution of the current 3T PCMRI is not sufficient for such a purpose owing to the small diameter of these vessels; however, with the higher resolution available using 7T PCMRI,<sup>25</sup> it might be feasible to explore this idea.

Of the biomechanical properties measured, only AL and CH changed significantly after treatment. A decrease in the AL after the IOP decrease was seen, without a corresponding change in the control eye. This finding is in accordance with published literature, where a decrease in the AL has been reported after IOP reduction.<sup>26,27</sup> Our results also showed an increase in CH in the treated eye, which also is in line with previous results,<sup>28–30</sup> although contrary results also exist.<sup>31</sup> Interestingly, a significant negative correlation was found between PI and IOP in the treated eye before treatment, but

not after the IOP had been decreased. This result could indicate that the capacity for cardiac-related arterial expansion in the eye is decreased when the IOP is high.

Strengths of this study were its prospective design, that all participants were previously untreated with IOP-lowering medications, and the fact that they then received latanoprost according to a standardized protocol. A potential limitation is that the untreated IOP level was not higher; in retrospect, an IOP greater than 30 mm Hg would have been preferable considering possible compensation of autoregulatory mechanisms. Our results suggest that if there exists a within-patient change in blood flow rate after an IOP reduction, it is less than the 2 mL/min assumed in the power calculation. However, given that only 15% to 20% (i.e., approximately 2 mL/min) of the OA blood flow rate are conveyed to vessels that supply the eye, a physiologically relevant difference could possibly be as small as 0.5 mL/min which means that a sample size of  $n = 30$  could give a type II error.

In summary, this study showed that blood flow in the OA measured with PCMRI was not affected by IOP reduction in previously untreated ocular hypertensive subjects. This outcome is most likely due to effective ocular autoregulation. We suggest that, to further explore the role of autoregulation and IOP in OA blood flow, a future study with a similar design should focus on patients with glaucoma, where the autoregulation can be expected to be dysfunctional, and ocular hypertension subjects with an IOP of more than 30 mm Hg, where autoregulation can be expected to be exhausted.

### Acknowledgments

This study was accepted for presentation at ARVO 2019 in Vancouver, but owing to a pilot strike, the presenting author was unable to attend.

Financial support was provided through regional agreements between Umea University and Vasterbotten County Council and also by grants from Knut and Alice Wallenberg Foundation, Crown Princess Margareta's Foundation, Ogonfonden, Insamlingsstiftelsen vid Umea universitet, the Swedish Medical Society Foundation, the Cronqvist Foundation, the Regné Foundation and Swedish Society for Medical Research. The funding organizations had no role in the design or conduct of this research. The authors alone are responsible for the content and writing of the paper.

Disclosure: **G. Jóhannesson**, Topcon, Thea, Santen, Allergan, Alcon/Novartis (F), Oculus (I); **S. Qvarlander**, None; **A. Wählin**, None; **K. Ambarki**, Siemens Healthineers (E); **P. Hallberg**, None; **A. Eklund**, None; **C. Lindén**, None

### References

- EGS. *Terminology and Guidelines for Glaucoma* 4th edition. Brussels, Belgium: European Glaucoma Society. 2014.
- Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121:2081–2090.
- Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol*. 2002;120:701–713; discussion 829–730.



4. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. *Arch Ophthalmol*. 2003;121:48–56.
5. Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma. *Prog Retin Eye Res*. 2002;21:359–393.
6. Riva CE, Hero M, Titze P, Petrig B. Autoregulation of human optic nerve head blood flow in response to acute changes in ocular perfusion pressure. *Graefes Arch Clin Exp Ophthalmol*. 1997;235:618–626.
7. Riva CE, Sinclair SH, Grunwald JE. Autoregulation of retinal circulation in response to decrease of perfusion pressure. *Invest Ophthalmol Vis Sci*. 1981;21:34–38.
8. Enzmann DR, Marks MP, Pelc NJ. Comparison of cerebral artery blood flow measurements with gated cine and ungated phase-contrast techniques. *J Magn Reson Imaging*. 1993;3:705–712.
9. Enzmann DR, Ross MR, Marks MP, Pelc NJ. Blood flow in major cerebral arteries measured by phase-contrast cine MR. *AJNR Am J Neuroradiol*. 1994;15:123–129.
10. Ambarki K, Hallberg P, Johannesson G, et al. Blood flow of ophthalmic artery in healthy individuals determined by phase-contrast magnetic resonance imaging. *Invest Ophthalmol Vis Sci*. 2013;54:2738–2745.
11. Harris A, Guidoboni G, Siesky B, et al. Ocular blood flow as a clinical observation: value, limitations and data analysis. *Prog Retin Eye Res*. 2020;100841.
12. Liu JH, Gokhale PA, Loving RT, Kripke DF, Weinreb RN. Laboratory assessment of diurnal and nocturnal ocular perfusion pressures in humans. *J Ocul Pharmacol Ther*. 2003;19:291–297.
13. Heiberg E, Sjogren J, Ugander M, Carlsson M, Engblom H, Arheden H. Design and validation of Segment—freely available software for cardiovascular image analysis. *BMC Med Imaging*. 2010;10:1.
14. Marjanovic I, Milic N, Martinez A. The impact of intraocular pressure reduction on retrobulbar hemodynamic parameters in patients with open-angle glaucoma. *Eur J Ophthalmol*. 2012;22:77–82.
15. Harris A, Migliardi R, Rechtman E, Cole CN, Yee AB, Garzoli HJ. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients. *Eur J Ophthalmol*. 2003;13:24–31.
16. Hommer A, Sperl P, Resch H, et al. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension. *J Ocul Pharmacol Ther*. 2012;28:569–575.
17. Inan UU, Ermis SS, Yucel A, Ozturk F. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. *Acta Ophthalmol Scand*. 2003;81:155–160.
18. Martinez A, Sanchez M. Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients. *Int J Clin Pract*. 2007;61:815–825.
19. Luo X, Shen YM, Jiang MN, Lou XF, Shen Y. Ocular blood flow autoregulation mechanisms and methods. *J Ophthalmol*. 2015;2015:864871.
20. Feke GT, Pasquale LR. Retinal blood flow response to posture change in glaucoma patients compared with healthy subjects. *Ophthalmology*. 2008;115:246–252.
21. Tribble JR, Anderson DR. Factors associated with intraocular pressure-induced acute visual field depression. *Arch Ophthalmol*. 1997;115:1523–1527.
22. Grunwald JE, Riva CE, Stone RA, Keates EU, Petrig BL. Retinal autoregulation in open-angle glaucoma. *Ophthalmology*. 1984;91:1690–1694.
23. Michalinos A, Zogana S, Kotsiomitris E, Mazarakis A, Troupis T. Anatomy of the ophthalmic artery: a review concerning its modern surgical and clinical applications. *Anat Res Int*. 2015;2015:591961.
24. Kaiser HJ, Schoetzau A, Stumpf D, Flammer J. Blood-flow velocities of the extraocular vessels in patients with high-tension and normal-tension primary open-angle glaucoma. *Am J Ophthalmol*. 1997;123:320–327.
25. Markenroth Bloch K, Toger J, Stahlberg F. Investigation of cerebrospinal fluid flow in the cerebral aqueduct using high-resolution phase contrast measurements at 7T MRI. *Acta Radiol*. 2018;59:988–996.
26. Husain R, Li W, Gazzard G, et al. Longitudinal changes in anterior chamber depth and axial length in Asian subjects after trabeculectomy surgery. *Br J Ophthalmol*. 2013;97:852–856.
27. Kim CS, Kim KN, Kang TS, Jo YJ, Kim JY. Changes in axial length and refractive error after noninvasive normalization of intraocular pressure from elevated levels. *Am J Ophthalmol*. 2016;163:132–139.e132.
28. Bolivar G, Sanchez-Barahona C, Teus M, et al. Effect of topical prostaglandin analogues on corneal hysteresis. *Acta Ophthalmol*. 2015;93:e495–e498.
29. Meda R, Wang Q, Paoloni D, Harasymowycz P, Brunette I. The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma. *Br J Ophthalmol*. 2017;101:120–125.
30. Tsikripis P, Papaconstantinou D, Koutsandrea C, Apostolopoulos M, Georgalas I. The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes. *Drug Des Devel Ther*. 2013;7:1149–1156.
31. Pillunat KR, Spoerl E, Terai N, Pillunat LE. Corneal biomechanical changes after trabeculectomy and the impact on intraocular pressure measurement. *J Glaucoma*. 2017;26:278–282.